The Summer 2026 GLP-1 Price Drop: Why Right Now Is the Cheapest Time to Start
Compounded semaglutide from $99/mo. Brand-name pills from $149/mo. Foundayo just launched. The compounding window may close this fall. Here's why now is the time.
If you've been watching GLP-1 medication prices from the sidelines, waiting for the right moment — this is it. Summer 2026 is the most affordable entry point in the history of GLP-1 weight loss treatment. Here's why, and exactly what you can expect to pay right now.
What Changed
Three things converged in early 2026 to drive prices to historic lows:
- Foundayo launch (April 2026): Eli Lilly's oral GLP-1 pill entered the market at $149/month self-pay — forcing price competition across the entire category
- Wegovy pill expansion: Novo Nordisk's oral semaglutide starts at $149/month through NovoCare, creating a brand-name floor price that compounding pharmacies must compete with
- Compounded semaglutide price war: With regulatory uncertainty around the FDA's 503B bulks list proposal, compounding providers are competing aggressively on price to attract and retain patients — driving starting prices as low as $99/month
The 2026 Price Landscape
| Provider | Type | Starting Price | Format | |
|---|---|---|---|---|
| GobyMeds | $99/mo | Compounded inj | Overnight free | Visit → Paid link |
| Oak Weight Loss | $130/mo flat | Compounded inj + oral | 3–5 days | Visit → Paid link |
| Direct Meds | $147/mo | Compounded inj + subling | 1 business day | Visit → Paid link |
| Foundayo (brand) | $149/mo | FDA-approved pill | Retail pharmacy | LillyDirect → |
| Wegovy pill (brand) | $149/mo | FDA-approved pill | Retail pharmacy | NovoCare → |
Why This Window May Not Last
The FDA's proposed removal of semaglutide and tirzepatide from the 503B bulks list — with a public comment period closing June 29, 2026 — could tighten compounded GLP-1 supply later this year. If the final rule restricts large-scale compounding, the $99–$147 compounded options may become harder to find or disappear entirely.
This doesn't mean rushing into treatment you're not ready for. But if you've been researching and waiting for the price to be right, the financial argument for starting in summer 2026 is stronger than it's ever been.